David Oxley, CEO of Vaccinogen and Member Board of Directors at Caladrix, shared a post on LinkedIn:
“Breaking news in oncology.
One antibody backbone, positive on 95–100% of tumors across six different adenocarcinomas, colorectal, pancreatic, gastric, breast, lung, and prostate, and it was not designed in a lab. Cancer patients’ own immune systems raised it.
Following ASCO, Vaccinogen has opened CTA-1 for evaluation.
In solid tumors, the chemistry rarely fails; the target does, and the lost cost shows up in Phase 3. TROP2, CEACAM5, mesothelin, and across 2025 and 2026 the collapse of the TIGIT class are the same lesson: a target chosen before anyone knew how it would behave inside a patient, and present on too few of the cells that matter.
CTA-1 is a fully human IgG1 that patients generated in vivo, under their own immune tolerance, against their own intact tumor, and it converged on a conserved malignant-epithelial signature that ordinary genomic discovery cannot see.
The read on CTA-1 is broad and homogeneous across adenocarcinoma. Due to the demand, we are putting CTA-1 in your hands on a non-exclusive basis to run the staining on your own tissue and try to break it. Because it is fully human, the same backbone can, in principle, travel into an ADC, a bispecific, or a radioligand without resolving the target! So, a positive evaluation represents a significant platform across your development portfolio.
If you build solid-tumor ADCs, bispecifics, or radioligands and your bottleneck is the target, read the piece linked, then email us at doxley@vaccinogentx.com. Our confidence means we will validate CTA-1 on your own tissue, at our cost, in 90 days. Try before you buy is the model.”
You can read more articles on David Oxley on OncoDaily.